Citi Sticks to Its Hold Rating for Evolution Mining (CAHPF)
In a report released today, Kate McCutcheon from Citi maintained a Hold rating on Evolution Mining (CAHPF – Research Report), with a price target of A$8.50. The company's shares closed today at $6.10.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, McCutcheon is a 4-star analyst with an average return of 8.0% and a 61.54% success rate. McCutcheon covers the Basic Materials sector, focusing on stocks such as Northern Star Resources Ltd, Evolution Mining , and Mineral Resources Limited.
Evolution Mining has an analyst consensus of Hold, with a price target consensus of $4.72.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
42 minutes ago
- Business Insider
Why Is Helius Medical Tech Stock (HSDT) Up 100% Today?
Helius Medical Technologies (HSDT) stock surged on Wednesday after the neurotech company announced an authorized claim for payment for its Portable Neuromodulation Stimulator (PoNS) from CVS Health (CVS) -owned Aetna Healthcare. This is the third time a major healthcare provider has offered to cover PoNS for a patient. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Dane Andreeff, President and CEO of Helius Medical Tech, said, 'We are actively pursuing broader in-network coverage for PoNS at list price from major commercial payers, while continuing to negotiate reimbursement on a case-by-case basis.' PoNS is an orally applied therapy that delivers neurostimulation via a non-implantable mouthpiece. HSDT stock rocketed 98.82% during pre-market trading on Wednesday. That's a welcome change from its 91.50% drop year-to-date and 94.88% fall over the past 12 months. Is Helius Medical Technologies Stock a Buy, Sell, or Hold? Wall Street's coverage of Helius Medical Technologies is thin, but TipRanks' AI analyst Spark fills that gap. Spark rates HSDT stock an Underperform (38) with a $1 price target. The AI analyst cites 'significant financial and operational challenges' as reasons for this rating and price.
Business Insider
42 minutes ago
- Business Insider
Barclays Remains a Buy on Oracle (ORCL)
Barclays analyst Raimo Lenschow reiterated a Buy rating on Oracle (ORCL – Research Report) today and set a price target of $202.00. The company's shares closed today at $176.38. Confident Investing Starts Here: Lenschow covers the Technology sector, focusing on stocks such as Microsoft, ServiceNow, and CoreWeave, Inc. Class A. According to TipRanks, Lenschow has an average return of 10.7% and a 60.00% success rate on recommended stocks. Currently, the analyst consensus on Oracle is a Moderate Buy with an average price target of $178.95, representing a 1.46% upside. In a report released today, Citizens JMP also maintained a Buy rating on the stock with a $205.00 price target. ORCL market cap is currently $497.7B and has a P/E ratio of 41.70. Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ORCL in relation to earlier this year. Last month, Leon Panetta, a Director at ORCL sold 17,500.00 shares for a total of $2,646,525.00.
Business Insider
an hour ago
- Business Insider
Catheter Precision Stock (VTAK) Rockets 170% on a Delayed Investor Reaction
Catheter Precision (VTAK) stock surged on Wednesday after the medical device company announced the first purchase order for its VIVO product. This is a non-invasive 3D imaging system to identify the origin of ventricular arrhythmias pre-procedure. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Catheter Precision reached an agreement with Sahlgrenska University Hospital for its VIVO devices. That's a major win for the company as this is Sweden's largest hospital with over 350,000 patients per year. It also has the largest ventricular ablation program in the region. David Jenkins, CEO of Catheter Precision, said, 'Creating strong partnerships with teaching hospitals enables new physicians to be trained with our products and creating a new opportunity for future sales when that physician leaves the teaching institution.' VTAK Stock Movement Today While the VIVO sales agreement was announced on Monday, investors only recently took notice of it. This delayed reaction resulted in a 170.1% rally in pre-market trading on Wednesday. This easily erases the stock's 49.69% drop year-to-date, but still leaves it well below its 52-week high of $6.40. Is Catheter Precision Stock a Buy, Sell, or Hold? Wall Street's coverage of Catheter Precision is lacking, but TipRanks' AI analyst, Spark, fills in that gap. Spark rates VTAK stock a Neutral (41) with no price target, citing 'significant financial challenges with persistent losses and negative cash flows' as reasons for this stance.
